Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with fEcal microbiota transfer (HERACLES)

Trial Profile

Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with fEcal microbiota transfer (HERACLES)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Maa-T-013 (Primary)
  • Indications Graft-versus-host disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms HERACLES
  • Sponsors MaaT Pharma
  • Most Recent Events

    • 21 Mar 2018 Dates are not mentioned in EudraCT please update once more information become available.
    • 17 Mar 2018 Status changed from planning to recruiting.
    • 13 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top